OncoCyte Corporation – Consensus Indicates Potential 6.7% Upside

Broker Ratings

OncoCyte Corporation found using ticker (OCX) now have 7 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 11 and 2 calculating the average target price we see 5.71. Given that the stocks previous close was at 5.35 this indicates there is a potential upside of 6.7%. The day 50 moving average is 3.59 and the 200 moving average now moves to 2.07. The market cap for the company is $379m. Company Website: http://www.oncocyte.com

OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index